Fulden Yumuk

[Hidehito HORINOUCHI @HHorinouchi]

🔥HARMONi-2: "Statistically significant overall survival (OS) benefit"
🆙 @AkesoInc @SMMT_TX 🔜 #WCLC26
👥Patients: Locally advanced or metastatic, PD-L1-positive (TPS ≥1%), EGFR/ALK wild-type NSCLC, treatment-naïve
3⃣Phase III
🎯OS HR 0.73 (95% CI: 0.57, 0.95)
🎯mOS 30.8m vs 22.6m
⚖️Ivonescimab monotherapy
⚖️Pembrolizumab monotherapy
🔢NCT05499390
#LCSM @OncoAlert @Larvol
🔗 https://t.co/HTPV1Hh500
🔗 https://t.co/TjeFeKibS1

[Stephen V Liu, MD @StephenVLiu]

Retrospective report on 54 pts with EGFR NSCLC transformed to SCLC shows better outcomes with chemo-immunotherapy over chemo alone. Clinical consideration is that IO and TKI do not partner well - so if TKI is suppressing some disease (including CNS), it would likely need to stop if IO started. This is an area where we need far more studies - and empiric strategies will only take us so far. There likely are some that benefit from IO (maybe bispecifics here) and some that do not and we need to be able to direct our patients to the best strategies but this space is quite poorly understood.

https://t.co/wSv3P58lg7

[Luis Moreno Sánchez @drluismorenos]

EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer-2026 Update. Part I

https://t.co/M2JsBqwAU7

EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer. Part II-2026 Update

https://t.co/JNfephHD5E

[Diego A. Díaz-García @diegoadiazg]

🫁 PD-L1 Negative NSCLC.

In a real-world cohort of 457 patients, nivolumab + ipilimumab + chemotherapy was associated with longer OS than pembrolizumab + chemotherapy in PD-L1 TPS <1% tumors:
• Median OS: 47.4 vs 16.6 months
• HR 0.50 (p=0.007)
No OS difference was observed in PD-L1 TPS ≥1%.

📖 Lung Cancer
DOI 👉🏻 https://t.co/I0ToWgihVK

#CánCare #NSCLC #lcsm #ThoracicOncology #Immunotherapy #PDL1

[Toni Choueiri, MD @DrChoueiri]

Detecting lung cancer 5 years before it happens, in @CellCellPress courtesy of the @CharlesSwanton group.

Astonishing translational work !

https://t.co/EvUmIGVLgs

[Erman Akkus @Erman_Akkus]

⭕️Tools to estimate ChT toxicity in older adults

#cancer #oncology #MedX ASCO-SEP @OncoAlert @realbowtiedoc

[Erman Akkus @Erman_Akkus]

🏥T4, MRF, CRM in rectal cancer for medical oncologists

✅All related but different concepts
➡️T4b but MRF- (e.g. upper third tm)
➡️MRF by MRI, CRM by pathological
➡️MRF- but CRM+ (e.g. technically hard surgery)

PS: prepared by AI. Surgeon, pathologist, radiologist colleagues may correct if wrong

#cancer #oncology #MedX #rectal #GI @OncoAlert

[Dr Joseph McCollom DO @realbowtiedoc]

Dr Sriram Yennu from #MDACC shows that combination of #exercise + #methylphenidate improved #CRF (cancer related fatigue) compared to #exercise + placebo for #pcsm on #ADT at #SymptomScience oral abstracts #ASCO26 #pallonc #supponc

@PallOncCoP
@MazieTsangMD
@DarcyBurbage
@Chaosdyna
@crisbergerot
@GretchenMcnally
@BbaharK
@asfeen_ummul
@veladconmigo
@FionnualaCrowle @OncoAlert🚨
#OncoAlertAF
@FadiHaddad_MD
@Abdallah81MD
@Erman_Akkus
@bavilima
@acampsmalea
@DrFMartinelli
@Dr_Ivanoncologo
@orellanauro
@FernandoOnco
@Lucarecco
@HHorinouchi
@ElisaAgostinett
@to_be_elizabeth
@BRicciutiMD
@nataliagandur
@GaiaGriguolo
@JankovicK
@weoncologists
@OncoReporte
@GIMedOnc
@MarioBalsaMD
@DrMirallas
@OscarTahuahua
@DrRishabhOnco
@UOzkerim
@Onco_Cifu88
@DraMartinezLago
@DaisukeKotani
@jillfeldman4
@IshwariaMD
@SrinishantR
@AjuVaniBabu
@rabrazzak
@TamrynGray
@anhbl9

[Yakup Ergün @dr_yakupergun]

#ASCO26

Approach for ycN0 disease after NAC

From the excellent discussion by Dr. Judy C. Boughey

[Grainne O'Kane @graokane]

SWOG S2001:maintenance olaparib/pembro v olaparib gBRCA1/2 #PDAC
➡️closed due to futility
➡️n = 73 mPFS 8.2 v6.4mths
➡️mOS 20 v 22.1mths
Higher ORR but need understand TiME HRD-PDAC better for better combo! #ASCO26
@ASCO @OncoAlert @pancanireland @KReissMD

[Uğur Özkerim @UOzkerim]

LORIN delivers one of the most impressive neoadjuvant targeted therapy datasets seen in stage III NSCLC.

🔹 pCR: 47%
🔹 MPR: 81%
🔹 R0 resection: 97%
🔹 Overall nodal downstaging: 90%

Perhaps the most striking finding: 72% of cN3 patients converted to pN0 after just 12 weeks of neoadjuvant lorlatinib.

#ASCO26 #ALK
@OncoAlert @StephenVLiu @OncoReporte @MedwatchKate @christine_lovly @RManochakian @weoncologists

[Hidehito HORINOUCHI @HHorinouchi]

🔥BREAKING‼️ @JAMA_current 🆙
🆙 #ASCO26 #LCSM Oral Abstract Session
🔥ALCHEMIST (EA5142): Adjuvant Nivolumab vs Observation in Resected NSCLC (EGFR/ALK-)
✅mDFS 71.3 vs 68.8mo (HR 0.97)
✅PD-L1≥50%: DFS HR 0.86 (p=0.22)
🎙️ @ChaftJamie
🔗 https://t.co/RtSVp4OY7g
@OncoAlert @Larvol @ASCO

[Rami Manochakian MD, FASCO @RManochakian]

🔥🚨@OncoAlert Hot off the press.

Just presented @ASCO #ASCO26 by Dr.
Chao Zhang.

⭐️#Promising & #Exciting Results of #LORIN Phase 2 trial of:

❇️#Neoadjuvant #Lorlatinib in Stage III #ALK+ #NSCLC.

✅#ORR 83.7%
✅#pCR 46.9% #MPR 81.3%
✅75% of unresectable Dx had conversion #Surgery.
✅1y #EFS: 97.1%

[OncLive.com @OncLive]

EMERALD-3: TACE + STRIDE +/- Lenvatinib vs. TACE alone:
✨️ Median PFS: 12.9 (STRIDE+TACE) vs. 8.1 (TACE) months
✨️ Lenvatinib 🟰 0 benefit, ⬆️ toxicity

⚡️Need OS data
⚡️Use Y90, not TACE
⚡️Patient selection is key
#ASCO26
@SKamath_MD @ASCO @CleClinicMD

[UT MD Anderson @UTMDAnderson]

Presented by Dr. Pavlos Msaouel at #ASCO26, a collaborative multi-institutional study identified EGFR as a key therapeutic vulnerability in SMARCB1-deficient renal medullary carcinoma, a rare and highly aggressive kidney cancer.

Panitumumab-based therapy produced a 53.9% response rate, including complete responses, in heavily pretreated patients, supporting a promising new treatment approach for this disease. @PavlosMsaouel #EndCancer

[Toni Choueiri, MD @DrChoueiri]

Great presentation by Dr. Pavlos Msaouel. Panitumumab-based EGFR blockade in SMARCB1-deficient renal medullary carcinoma: ORR 53.9% (15.4% CR) and mOS 9.5 mo in heavily pretreated pts, far exceeding historical benchmarks. Wild-type EGFR dependency as a new therapeutic vulnerability in this rare, aggressive disease. #ASCO26 #RCC @OncoAlert @ASCO @OncBrothers

[Toni Choueiri, MD @DrChoueiri]

CaboNivo final results in non-clear cell RCC presented by Dr Darren Feldman: ORR 43% in Cohort 1 (papillary, unclassified, tRCC), with a striking 88% ORR in FH-deficient RCC. mPFS 11 mo, mOS 28 mo. No responses in chromophobe RCC. CaboNivo confirmed as a standard 1L option for these rare subtypes. #ASCO26 #RCC @OncoAlert @ASCO @OncBrothers

[NEJM @NEJM]

Presented at #ASCO26:

Among patients with previously treated metastatic pancreatic ductal adenocarcinoma, the RAS(ON) inhibitor daraxonrasib led to significantly longer overall survival and progression-free survival than chemotherapy. Full phase 3 RASolute 302 trial results: https://t.co/xwLWBZYRzq

@ASCO

[Yüksel Ürün @DrYukselUrun]

This is not simply a new pancreatic cancer drug.

It is a reminder that even “undruggable” biology can become treatable with persistence.

Daraxonrasib doubled median OS vs chemotherapy in RAS G12 metastatic pancreatic cancer: 13.2 vs 6.6 months.
A remarkable ASCO moment.
#ASCO26
@DrChoueiri @TiansterZhang @CathyEngMD @montypal @tompowles1 @brian_rini @cdanicas @GlopesMd @PGrivasMDPhD @nataliagandur @yekeduz_emre @neerajaiims @ASCO @ONCOassist @OpenMedicineHQ @MedwatchKate @scserendipity1 @CParkMD @urotoday @OncLive @crisbergerot @urologysummit @SuyogCancer @Larvol @IMG_Oncologists

[OncLive.com @OncLive]

🚨 @ASCO #ASCO26 Update: Perioperative #apalutamide + ADT improved metastasis-free survival and pathologic responses vs placebo + ADT in high-risk localized prostate cancer.

The trial sets a new standard of care for this population: https://t.co/N3N6ggFYjC

@DanaFarber @harvardmed #pcsm #medtwitter #oncology